Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Ferris, R.; Blumenschein, G.; Fayette, J.; Guigay, J.; Colevas, A.; Licitra, L.; Harrington, K.; Kasper, S.; Vokes, E.; Even, C.; Worden, F.; Saba, N.; Iglesias Docampo, L.; Haddad, R.; Rordorf, T.; Kiyota, N.; Tahara, M.; Monga, M.; Lynch, M.; Geese, W.; Kopit, J.; Shaw, J.; Gillison, M.

doi:10.1056/NEJMOA1602252

Public

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Shared by NobleBlocks on Oct 8, 2016 • 12:00 AM UTC

Authors:

R. Ferris

G. Blumenschein

J. Fayette

Abstract

BACKGROUND Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti–programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition. METHOD...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!